Prevention and treatment of nonpostmenopausal osteoporosis

被引:19
作者
Hansen, LB
Vondracek, SF
机构
[1] Univ Colorado, Hlth Sci Ctr, Sch Pharm, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Dept Clin Pharm & Family Med, Denver, CO 80262 USA
[3] Univ Colorado, Hlth Sci Ctr, Dept Clin Pharm, Denver, CO 80262 USA
关键词
adolescents; anorexia netvosa; anticoagulants; anticonvulsants; antineoplastic agents; costs; heparin; hyperthyroidism; inflammatory bowel diseases; lung diseases; methotrexate; osteoporosis; postmenopause; quality of life; steroids; cortico-; toxicity; transplantation; warfarin;
D O I
10.1093/ajhp/61.24.2637
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The causes, prevention, and treatment of osteoporosis in specific populations are discussed. Summary. Osteoporosis and osteopenia affect 44 million women and men ages 50 years or older. Fractures are the most devastating consequence of this disease and significantly affect quality of life, activities of daily living, survival, and health care costs. Most osteoporosis research has focused on postmenopausal women, but several other populations are at risk for osteoporosis, such as patients taking certain medications that affect bone health and those with various health conditions that cause bone loss, including anorexia nervosa, hyperthyroidism, organ transplantation, chronic obstructive pulmonary disease, and inflammatory bowel disease. Glucocorticoids are the most common secondary cause of osteoporosis. Other medications that have been implicated as secondary causes include anticonvulsants, heparin, warfarin, and methotrexate. Preventing osteoporosis may be even more important in adolescence than after menopause. Conclusion. Osteoporosis needs to be recognized, monitored, and appropriately treated in patients taking medications that affect bone health and in patients with conditions that increase the risk of osteoporosis.
引用
收藏
页码:2637 / 2654
页数:18
相关论文
共 208 条
[1]  
AACE Hypogonadism TF, 2002, ENDOCR PRACT, V8, P439
[2]   Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis [J].
Adachi, JD ;
Bensen, WG ;
Brown, J ;
Hanley, D ;
Hodsman, A ;
Josse, R ;
Kendler, DL ;
Lentle, B ;
Olszynski, W ;
SteMarie, LG ;
Tenenhouse, A ;
Chines, AA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) :382-387
[3]  
Adachi JD, 2001, ARTHRITIS RHEUM-US, V44, P202, DOI 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO
[4]  
2-W
[5]  
ADACHI JD, 1994, J RHEUMATOL, V21, P1922
[6]   The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada [J].
Adachi, JD ;
Ioannidis, G ;
Berger, C ;
Joseph, L ;
Papaioannou, A ;
Pickard, L ;
Papadimitropoulos, EA ;
Hopman, W ;
Poliquin, S ;
Prior, JC ;
Hanley, DA ;
Olszynski, WP ;
Anastassiades, T ;
Brown, JP ;
Murray, T ;
Jackson, SA ;
Tenenhouse, A .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (11) :903-908
[7]  
Alaimo K, 1994, DIETARY INTAKE VITAM, V258
[8]   Estimated dietary calcium intake and food sources for adolescent females: 1980-92 [J].
Albertson, AM ;
Tobelmann, RC ;
Marquart, L .
JOURNAL OF ADOLESCENT HEALTH, 1997, 20 (01) :20-26
[9]  
Altose MD, 2000, NEW ENGL J MED, V343, P1902
[10]  
American Association of Clinical Endocrinologists Osteoporosis Task Force, 2001, Endocr Pract, V7, P293